Oncimmune Hits IPO Target
This article was originally published in Clinica
Executive Summary
Early cancer detection specialist Oncimmune has joined AIM, the London Stock Exchange’s international market for emerging companies, after successfully completing its initial public offering and raising £11m ($15.7m) in gross proceeds. The company’s market capitalization on admission to AIM is around £66.3m; it is trading under the symbol “ONC.L”.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q2 2016
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Oncimmune Taps Former Luminex, Abbott Exec To Head Asia Sales
Early lung cancer detection company Oncimmune gears up to target Asian markets with the appointment of Maarten Brusse as chief commercial officer for the region.
Q2 Breathes A Little Life Into Medtech IPO Scene
After a lackluster first quarter, the medtech IPO scene is gradually livening up with several companies their shares successfully floated on the public markets for the first time in the second quarter. But activity levels are still a far cry from the bonanza of 2015.